IDEXX Laboratories (IDXX) to Release Earnings on Thursday

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) is projected to issue its Q1 2025 quarterly earnings data before the market opens on Thursday, May 1st. Analysts expect the company to announce earnings of $2.93 per share and revenue of $998.25 million for the quarter.

IDEXX Laboratories Trading Down 0.0 %

IDXX traded down $0.02 during trading on Tuesday, reaching $433.98. The company had a trading volume of 141,928 shares, compared to its average volume of 632,251. IDEXX Laboratories has a 12-month low of $356.14 and a 12-month high of $548.88. The firm's 50-day simple moving average is $419.59 and its 200 day simple moving average is $428.50. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31. The company has a market cap of $35.17 billion, a price-to-earnings ratio of 40.63, a PEG ratio of 3.41 and a beta of 1.50.

Insider Activity at IDEXX Laboratories

In other news, Director M Anne Szostak sold 3,000 shares of IDEXX Laboratories stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the transaction, the director now owns 3,061 shares in the company, valued at approximately $1,426,242.34. The trade was a 49.50 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP George Fennell sold 9,986 shares of IDEXX Laboratories stock in a transaction on Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the transaction, the executive vice president now owns 8,176 shares of the company's stock, valued at approximately $3,781,645.28. The trade was a 54.98 % decrease in their position. The disclosure for this sale can be found here. 0.98% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several research analysts recently weighed in on the company. Morgan Stanley dropped their price target on IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating on the stock in a research report on Wednesday, January 29th. Bank of America lifted their target price on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a research note on Tuesday, February 4th. StockNews.com cut IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Saturday, April 12th. Stifel Nicolaus dropped their price target on shares of IDEXX Laboratories from $450.00 to $420.00 and set a "hold" rating on the stock in a research note on Monday, April 14th. Finally, Barclays boosted their target price on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an "overweight" rating in a report on Tuesday, February 4th. Four research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, IDEXX Laboratories currently has a consensus rating of "Moderate Buy" and an average price target of $523.75.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.